MeDIAR: Multi-Drug Adverse Reactions Analytics

Adverse drug reactions (ADRs) caused by drug-drug interactions (DDI) are a major cause of morbidity and mortality worldwide. There is a growing need for computing-supported methods that facilitate the automated signaling of DDI related ADRs (DIARs) that otherwise would remain undiscovered in millions of ADR reports. In this demonstration, we showcase our MeDIAR technology – an end-to-end DIAR signal generation, exploration and validation solution for pharmaceutical regulatory agencies to detect true DIAR signals from a drug surveillance database. MeDIAR's innovations include an efficient rule-driven learning algorithm for deriving DIAR signals from ADR reports, an innovative scoring methodology based on the proposed contextual association cluster model to rank the generated signals by their importance. Further, these ranked signals are augmented with meta information such as their significance level and their severity, along with links to their supporting ADR reports. Lastly, MeDIAR features an interactive visual analytics interface to support drug safety evaluators in reviewing and discovering unknown severe DIARs.